Danofloxacin
Brand names: Advocin · Active ingredient: Danofloxacin Mesylate
In short: For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida in beef cattle and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida.
What is Danofloxacin used for?
For the treatment of bovine respiratory disease (BRD) associated with Mannheimia
haemolytica and Pasteurella multocida in beef cattle and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia
haemolytica and Pasteurella multocida.
âš Boxed warning (FDA's strongest warning)
Animals intended for human consumption must not be slaughtered within 4 days from the last treatment. Do not use in cattle intended for dairy production. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
For use in animals only. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if irritation persists following ocular or dermal exposures. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. To report adverse reactions or to obtain a copy of the Safety Data Sheet (SDS), call 1-888-963-8471.
Danofloxacin dosage
Care should be taken to dose accurately. Administered dose volume should not exceed 15 mL per injection site.
Single-Dose Therapy (BRD Treatment and Control in Cattle at High Risk):
Administer subcutaneously at 8 mg/kg of body weight (2 mL/100 lb) as a one-time injection.
Multi-Day Therapy (BRD Treatment):
Administer subcutaneously at 6 mg/kg of body weight (1.5 mL/100 lb) with this treatment repeated once approximately 48 hours following the first injection.
Dose Volume (mL)
Cattle Weight(lb) | 6 mg/kg, given twice,48 hours apart (treatment) | 8 mg/kg given once (treatment and control in cattle at high risk)
50 | 0.75 | 1
100 | 1.5 | 2
150 | 2.25 | 3
200 | 3 | 4
250 | 3.75 | 5
300 | 4.5 | 6
400 | 6 | 8
500 | 7.5 | 10
600 | 9 | 12
700 | 10.5 | 14
800 | 12 | 16Administered dose volume should not exceed 15 mL per injection site.
900 | 13.5 | 18
1000 | 15 | 20
* Administered dose volume should not exceed 15 mL per injection site.
Warnings & precautions
The effects of danofloxacin on bovine reproductive performance, pregnancy, and lactation have not been determined.
Subcutaneous injection can cause a transient local tissue reaction that may result in trim loss of edible tissue at slaughter.
Quinolone-class drugs should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation, which may lead to convulsive seizures.
Quinolone-class drugs have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature, rapidly growing animals of various species. Refer to Animal Safety for information specific to danofloxacin.
Danofloxacin side effects
A hypersensitivity reaction was noted in 2 healthy calves treated with ADVOCIN in a laboratory study. In one location of a multi-site field trial, one out of the 41 calves treated with 6 mg/kg q 48 hours showed lameness on Day 6 only. In this same field trial location one of 38 calves treated with 8 mg/kg once became lame 4 days after treatment and remained lame on the last day of the study (Day 10). Another calf in the same treatment group developed lameness on the last day of the study.
About this medicine
ADVOCIN is a sterile injectable solution containing danofloxacin mesylate, a synthetic fluoroquinolone antimicrobial agent. Danofloxacin mesylate is the non-proprietary designation for (1S)-1cyclopropyl-6-fluoro-1,4-dihydro-7-(5-methyl-2,5-diazabicyclo [2.2.1]hept-2-yl)-4-oxo-3-quinolone carboxylic acid monomethanesulfonate. The empirical formula is C19H20FN3O3 • CH3SO3H and the molecular weight is 453.49.
Figure 1. The chemical structure of danofloxacin mesylate.
Each mL contains 180 mg of danofloxacin as the mesylate salt, 200 mg 2-pyrrolidone, 50 mg polyvinyl pyrrolidone, 20.3 mg heavy magnesium oxide, 2.5 mg phenol, 5 mg monothioglycerol, hydrochloric acid or sodium hydroxide as needed to adjust pH, nitrogen headspace and water for injection, q.s.
How it works: Danofloxacin distributes extensively throughout the body, as evidenced by a steady state volume of distribution (VDss) in cattle exceeding 1 L/kg. Danofloxacin concentrations in the lung homogenates markedly exceed those observed in plasma, further suggesting extensive distribution to the indicated site of infection. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID d22c22fc-d530-423c-8d78-ca95fe195ba1. Read the full official label on DailyMed.